Evidence map›Paper›PMID 33723220›Full record

Trial reportTranslational psychiatry2021

Depression treatment response to ketamine: sex-specific role of interleukin-8, but not other inflammatory markers.

Jennifer L Kruse, Megha M Vasavada, Richard Olmstead, Gerhard Hellemann, Benjamin Wade, Elizabeth C Breen, John O Brooks, Eliza Congdon, Randall Espinoza, Katherine L Narr and 1 more

Registry-linked trialOpen access · goldAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Translational psychiatry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02165449 (Translational Biomarkers of Fast Acting Therapies in Major Depression), which is not on this map. Cited by 31 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 3 pooled it
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02165449 phase1completednot on this map

Translational Biomarkers of Fast Acting Therapies in Major Depression

TypeinterventionalSponsorUniversity of California, Los AngelesRan2014 to 2019Enrolled60ConditionsMajor Depressive DisorderArmsKetamine
3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 3 syntheses or guidelines pooled it, 43 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Towards causal inference-based antidepressant selection with brain and blood biomarkers.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Trial
  5. Trial
  6. Trial
  7. Article
  8. Sex-specific Serum Biomarker Associations with Antidepressant Treatment Outcomes in Depressive Disorders.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2026
    Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Jennifer L KruseCousins Center for Psychoneuroimmunology, University of California at Los Angeles, Los Angeles, CA, USA. jkruse@mednet.ucla.edu.ORCID 0000-0003-0628-3921
Megha M VasavadaDepartment of Neurology, University of California at Los Angeles, Los Angeles, CA, USA.
Richard OlmsteadCousins Center for Psychoneuroimmunology, University of California at Los Angeles, Los Angeles, CA, USA.
Gerhard HellemannJane and Terry Semel Institute for Neuroscience and Human Behavior at UCLA, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, Los Angeles, CA, USA.ORCID 0000-0003-2449-7704
Benjamin WadeDepartment of Neurology, University of California at Los Angeles, Los Angeles, CA, USA.
Elizabeth C BreenCousins Center for Psychoneuroimmunology, University of California at Los Angeles, Los Angeles, CA, USA.
John O BrooksJane and Terry Semel Institute for Neuroscience and Human Behavior at UCLA, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, Los Angeles, CA, USA.
Eliza CongdonJane and Terry Semel Institute for Neuroscience and Human Behavior at UCLA, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, Los Angeles, CA, USA.
Randall EspinozaJane and Terry Semel Institute for Neuroscience and Human Behavior at UCLA, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, Los Angeles, CA, USA.ORCID 0000-0003-2895-4212
Katherine L NarrJane and Terry Semel Institute for Neuroscience and Human Behavior at UCLA, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine, Los Angeles, CA, USA.
Michael R IrwinCousins Center for Psychoneuroimmunology, University of California at Los Angeles, Los Angeles, CA, USA.ORCID 0000-0002-1502-8431
University of California, Los Angeles · US

Funding

UCLA Clinical Translational Science InstituteUL1TR001881 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ARLEEN F. BROWN, ARASH NAEIM · 2016 to 2026
$118.1M
Aging: Sleep and Inflammatory Mechanisms in Depression PreventionR01AG026364 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI IRWIN, MICHAEL R · 2005 to 2015
$5.8M
Perturbation of the treatment resistant depression connectome by fast-acting therapiesU01MH110008 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ESPINOZA, RANDALL, NARR, KATHERINE L · 2016 to 2019
$5.5M
Imaging biomarkers of ECT response in major depressive disorderR01MH092301 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ESPINOZA, RANDALL, NARR, KATHERINE L · 2011 to 2015
$4.0M
Sleep, Inflamation, and Depression Occurrence in Breast Cancer SurvivorsR01CA160245 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI IRWIN, MICHAEL R · 2012 to 2016
$3.9M
Chronic Moderate Sleep Restriction in Older Long and Older Average SleepersR01HL095799 · NHLBI · UNIVERSITY OF SOUTH CAROLINA AT COLUMBIA · PI IRWIN, MICHAEL R, JEAN-LOUIS, GIRARDIN · 2011 to 2015
$3.8M
Mechanisms of Sleep Disruption HyperalgesiaR01DA032922 · NIDA · JOHNS HOPKINS UNIVERSITY · PI IRWIN, MICHAEL R, SMITH, MICHAEL T · 2012 to 2016
$2.7M
Tai Chi Effects on Chronic Insomnia in Breast Cancer Survivors: Immune MechanismsR01CA119159 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI IRWIN, MICHAEL R · 2006 to 2010
$2.2M
Subjective Social Isolation and Sleep Disturbances: Inflammatory Mechanisms in AgR01AG034588 · NIA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI IRWIN, MICHAEL R · 2009 to 2013
$1.9M
Biomarkers of fast acting therapies in major depressionK24MH102743 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI NARR, KATHERINE L · 2014 to 2018
$889k
Depression Response to Fast-Acting Treatments: Inflammation and Reward MechanismsK23MH116127 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KRUSE, JENNIFER · 2018 to 2021
$790k
NCATS NIH HHS UL1 TR001881NCI NIH HHS R01 CA119159NCI NIH HHS R01 CA160245NHLBI NIH HHS R01 HL095799NIA NIH HHS R01 AG026364NIA NIH HHS R01 AG034588NIDA NIH HHS R01 DA032922NIMH NIH HHS K23 MH116127NIMH NIH HHS K24 MH102743NIMH NIH HHS R01 MH092301NIMH NIH HHS U01 MH110008U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) K24MH102743U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) R01MH092301U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (NIMH) U01MH110008
6 · The paper itself

Abstract

Inflammation plays a role in depression pathophysiology and treatment response, with effects varying by sex and therapeutic modality. Lower levels of interleukin(IL)-8 predict depression response to antidepressant medication and to electroconvulsive therapy (ECT), although ECT effects are specific to females. Whether IL-8 predicts depression response to ketamine and in a sex-specific manner is not known. Here, depressed patients (n = 46; female, n = 17) received open label infusion of ketamine (0.5 mg/kg over 40 min; NCT02165449). Plasma levels of IL-8 were evaluated at baseline and post-treatment. Baseline levels of IL-8 had a trending association with response to ketamine, depending upon sex (responder status × sex interaction: p = 0.096), in which lower baseline levels of IL-8 in females (p = 0.095) but not males (p = 0.96) trended with treatment response. Change in levels of IL-8 from baseline to post-treatment differed significantly by responder status (defined as ≥50% reduction in Hamilton Depression Rating Scale [HAM-D] Score), depending upon sex (responder status × sex × time interaction: F(1,42)=6.68, p = 0.01). In addition, change in IL-8 interacted with sex to predict change in HAM-D score (β = -0.63, p = 0.003); increasing IL-8 was associated with decreasing HAM-D score in females (p = 0.08) whereas the inverse was found in males (p = 0.02). Other inflammatory markers (IL-6, IL-10, tumor necrosis factor-α, C-reactive protein) were explored with no significant relationships identified. Given these preliminary findings, further evaluation of sex differences in the relationship between IL-8 and treatment response is warranted to elucidate mechanisms of response and aid in the development of personalized approaches to depression treatment.

Indexed as

Electroconvulsive TherapyKetamineDepressionFemaleHumansInterleukin-8MalePsychiatric Status Rating ScalesSex FactorsTreatment OutcomeInterleukin-8Ketamine

Identifiers

PMID33723220
PMCPMC7960960
OpenAlexW3137344175

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.